OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy OPRX?
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPRX
Wall Street analysts forecast OPRX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.090
Low
17.00
Averages
24.33
High
32.00
Current: 5.090
Low
17.00
Averages
24.33
High
32.00
About OPRX
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OptimizeRx Exceeds Expectations with Strong Q1 Growth
- Performance Exceeds Expectations: OptimizeRx Corp (NASDAQ:OPRX) surpassed consensus estimates for both revenue and net income in Q1 2026, demonstrating a robust 60% growth in its AI-driven DApp solution, indicating strong product-market fit and customer adoption, which may enhance market share further.
- Revenue Structure Shift: The company is transitioning its revenue mix towards subscription models, a strategy that not only improves revenue visibility and predictability but also presents significant growth opportunities with mid-tier and long-tail life science companies, potentially strengthening long-term competitiveness.
- Gross Margin Optimization: Through gross margin optimization initiatives, OptimizeRx anticipates achieving a gross margin of over 60% for the full year 2026, despite a 10% decline in Q1 revenue compared to the same period in 2025, as margin improvements may help alleviate pressures from revenue declines.
- Cautious Revenue Guidance: Due to macroeconomic factors and cautious budget allocations from clients, OptimizeRx has updated its revenue guidance for 2026, now expecting revenue between $95 million and $100 million, reflecting the company's clear understanding of future market uncertainties.
See More
OptimizeRx Q1 2026 Earnings Call Insights
- Revenue Decline: OptimizeRx reported Q1 2026 revenue of $19.8 million, a 10% decrease from $21.9 million in Q1 2025, primarily due to ongoing softness in contracted revenue linked to last year's most favored nation pricing dynamics and macroeconomic factors, impacting financial stability.
- Cost Optimization Measures: The company expects to reduce cash operating expenses by approximately $3 million annually through cost structure alignment, with an anticipated $1 million benefit in 2026, which will help improve profitability and cash flow.
- Platform Distribution Transformation: OptimizeRx is enabling demand-side platforms controlling over 80% of digital promotional dollars to connect directly to its proprietary EHR network, a strategic shift expected to enhance utilization and strengthen market competitiveness.
- 2026 Guidance Adjustment: The company revised its 2026 revenue outlook to a range of $95 million to $100 million, reflecting a cautious stance on future revenue, while maintaining adjusted EBITDA guidance at $21 million to $25 million, indicating ongoing focus on profitability.
See More
OptimizeRx Scheduled to Announce Q1 Earnings Results
- Earnings Announcement Date: OptimizeRx (OPRX) is set to release its Q1 2023 earnings report on May 12 after market close, with consensus EPS estimate at $0.00, reflecting a 100% year-over-year decline, and revenue estimate at $18.35 million, down 16.2% year-over-year, indicating significant challenges ahead for the company.
- Historical Performance Review: Over the past two years, OPRX has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, although recent estimate revisions suggest a cautious outlook from the market regarding its future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and four downward revisions, while revenue estimates have experienced no upward revisions and six downward revisions, indicating a weakening confidence among analysts regarding the company's prospects.
- Long-term Outlook: OptimizeRx has set a revenue target of $109 million to $114 million for 2026 in its Q4 earnings report, and despite the cautious outlook driven by market shifts, the company is actively working to adapt to the new market environment to achieve growth.
See More
OptimizeRx Launches New Programmatic Connection Point
- Programmatic Market Access: OptimizeRx's launch of a new programmatic connection point enables media buyers to activate scalable clinical advertising campaigns within existing workflows, potentially driving the company's penetration into the 90% of U.S. digital display ad spend market.
- Efficient Ad Integration: By activating EHR advertising directly through DSPs, media buyers can manage reach, frequency, and scale more quickly, enhancing the efficiency and effectiveness of ad placements to meet the life sciences industry's demand for precision marketing.
- Enhanced DSP Value: DSPs can now integrate OptimizeRx's EHR publisher network directly into their native platforms, providing authenticated, bot-free EHR inventory that helps clients capture a larger share of the $19 billion pharma digital ad market.
- Strategic Market Advantage: OptimizeRx's CEO noted that this launch not only expands access to key clinical moments but also opens new opportunities for DSPs seeking competitive advantages in the life sciences market, fostering stronger client relationships and increasing industry revenues.
See More
OptimizeRx Shares Rise 5.9% Amid Strong Demand
- Stock Price Surge: OptimizeRx shares rose 5.9% to $7.18 in the last trading session, driven by impressive volume and reflecting strong market demand for its Dynamic Audience Activation Platform (DAAP), despite an 11.3% decline over the past four weeks.
- Customer Base Expansion: The company maintains strong engagement with existing clients while adding new customers, particularly in the mid-tier and long-tail life sciences sector, which management views as highly attractive and likely to drive future revenue growth.
- AI Opportunities: OptimizeRx positions AI as a tailwind rather than a disruption risk, anticipating that it will free up to 50% of marketing budgets currently allocated to content creation, allowing for reallocation towards marketing execution and audience reach, enhancing competitive advantage.
- Future Financial Outlook: Management projects 2026 revenue between $109 million and $114 million, with adjusted EBITDA expected in the range of $21 million to $25 million, although the upcoming quarterly earnings are forecasted at $0.02 per share, representing a 75% year-over-year decline.
See More
Three Strong Value Stocks to Consider
- OptimizeRx Earnings Growth: OptimizeRx Corporation (OPRX) holds a Zacks Rank #1, with the consensus estimate for its current year earnings rising by 12.6% over the past 60 days, indicating strong growth potential in the digital healthcare technology sector.
- Envista Profit Increase: Envista Holdings Corporation (NVST) also carries a Zacks Rank #1, and its current year earnings estimate has increased by 11.9% in the last 60 days, reflecting its sustained competitiveness in the dental products market.
- Strattec Security Growth: Strattec Security Corporation (STRT) maintains a Zacks Rank #1, with next year's earnings expected to grow by 19.3%, showcasing a robust development trend in the automotive technology sector.
- Significant Valuation Advantage: All three companies exhibit low price-to-earnings ratios, with OptimizeRx at 6.53, Envista at 17.50, and Strattec at 11.84, all below their respective industry averages, highlighting their strong investment value.
See More
OptimizeRx Exceeds Expectations with Strong Q1 Growth
- Performance Exceeds Expectations: OptimizeRx Corp (NASDAQ:OPRX) surpassed consensus estimates for both revenue and net income in Q1 2026, demonstrating a robust 60% growth in its AI-driven DApp solution, indicating strong product-market fit and customer adoption, which may enhance market share further.
- Revenue Structure Shift: The company is transitioning its revenue mix towards subscription models, a strategy that not only improves revenue visibility and predictability but also presents significant growth opportunities with mid-tier and long-tail life science companies, potentially strengthening long-term competitiveness.
- Gross Margin Optimization: Through gross margin optimization initiatives, OptimizeRx anticipates achieving a gross margin of over 60% for the full year 2026, despite a 10% decline in Q1 revenue compared to the same period in 2025, as margin improvements may help alleviate pressures from revenue declines.
- Cautious Revenue Guidance: Due to macroeconomic factors and cautious budget allocations from clients, OptimizeRx has updated its revenue guidance for 2026, now expecting revenue between $95 million and $100 million, reflecting the company's clear understanding of future market uncertainties.
See More
OptimizeRx Q1 2026 Earnings Call Insights
- Revenue Decline: OptimizeRx reported Q1 2026 revenue of $19.8 million, a 10% decrease from $21.9 million in Q1 2025, primarily due to ongoing softness in contracted revenue linked to last year's most favored nation pricing dynamics and macroeconomic factors, impacting financial stability.
- Cost Optimization Measures: The company expects to reduce cash operating expenses by approximately $3 million annually through cost structure alignment, with an anticipated $1 million benefit in 2026, which will help improve profitability and cash flow.
- Platform Distribution Transformation: OptimizeRx is enabling demand-side platforms controlling over 80% of digital promotional dollars to connect directly to its proprietary EHR network, a strategic shift expected to enhance utilization and strengthen market competitiveness.
- 2026 Guidance Adjustment: The company revised its 2026 revenue outlook to a range of $95 million to $100 million, reflecting a cautious stance on future revenue, while maintaining adjusted EBITDA guidance at $21 million to $25 million, indicating ongoing focus on profitability.
See More
OptimizeRx Scheduled to Announce Q1 Earnings Results
- Earnings Announcement Date: OptimizeRx (OPRX) is set to release its Q1 2023 earnings report on May 12 after market close, with consensus EPS estimate at $0.00, reflecting a 100% year-over-year decline, and revenue estimate at $18.35 million, down 16.2% year-over-year, indicating significant challenges ahead for the company.
- Historical Performance Review: Over the past two years, OPRX has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, although recent estimate revisions suggest a cautious outlook from the market regarding its future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and four downward revisions, while revenue estimates have experienced no upward revisions and six downward revisions, indicating a weakening confidence among analysts regarding the company's prospects.
- Long-term Outlook: OptimizeRx has set a revenue target of $109 million to $114 million for 2026 in its Q4 earnings report, and despite the cautious outlook driven by market shifts, the company is actively working to adapt to the new market environment to achieve growth.
See More
OptimizeRx Launches New Programmatic Connection Point
- Programmatic Market Access: OptimizeRx's launch of a new programmatic connection point enables media buyers to activate scalable clinical advertising campaigns within existing workflows, potentially driving the company's penetration into the 90% of U.S. digital display ad spend market.
- Efficient Ad Integration: By activating EHR advertising directly through DSPs, media buyers can manage reach, frequency, and scale more quickly, enhancing the efficiency and effectiveness of ad placements to meet the life sciences industry's demand for precision marketing.
- Enhanced DSP Value: DSPs can now integrate OptimizeRx's EHR publisher network directly into their native platforms, providing authenticated, bot-free EHR inventory that helps clients capture a larger share of the $19 billion pharma digital ad market.
- Strategic Market Advantage: OptimizeRx's CEO noted that this launch not only expands access to key clinical moments but also opens new opportunities for DSPs seeking competitive advantages in the life sciences market, fostering stronger client relationships and increasing industry revenues.
See More
OptimizeRx Shares Rise 5.9% Amid Strong Demand
- Stock Price Surge: OptimizeRx shares rose 5.9% to $7.18 in the last trading session, driven by impressive volume and reflecting strong market demand for its Dynamic Audience Activation Platform (DAAP), despite an 11.3% decline over the past four weeks.
- Customer Base Expansion: The company maintains strong engagement with existing clients while adding new customers, particularly in the mid-tier and long-tail life sciences sector, which management views as highly attractive and likely to drive future revenue growth.
- AI Opportunities: OptimizeRx positions AI as a tailwind rather than a disruption risk, anticipating that it will free up to 50% of marketing budgets currently allocated to content creation, allowing for reallocation towards marketing execution and audience reach, enhancing competitive advantage.
- Future Financial Outlook: Management projects 2026 revenue between $109 million and $114 million, with adjusted EBITDA expected in the range of $21 million to $25 million, although the upcoming quarterly earnings are forecasted at $0.02 per share, representing a 75% year-over-year decline.
See More
Three Strong Value Stocks to Consider
- OptimizeRx Earnings Growth: OptimizeRx Corporation (OPRX) holds a Zacks Rank #1, with the consensus estimate for its current year earnings rising by 12.6% over the past 60 days, indicating strong growth potential in the digital healthcare technology sector.
- Envista Profit Increase: Envista Holdings Corporation (NVST) also carries a Zacks Rank #1, and its current year earnings estimate has increased by 11.9% in the last 60 days, reflecting its sustained competitiveness in the dental products market.
- Strattec Security Growth: Strattec Security Corporation (STRT) maintains a Zacks Rank #1, with next year's earnings expected to grow by 19.3%, showcasing a robust development trend in the automotive technology sector.
- Significant Valuation Advantage: All three companies exhibit low price-to-earnings ratios, with OptimizeRx at 6.53, Envista at 17.50, and Strattec at 11.84, all below their respective industry averages, highlighting their strong investment value.
See More
